What should a clinical trial site readiness checklist include?

A site is ready when its investigator and staff are qualified, trained on the protocol and on the delegation record, ethics and regulatory approvals and signed agreements are on file, and the essential records expected before the trial starts are in place (ICH E6(R3) C.2.5).

Product, equipment and systems must also be ready, with access for every delegated user.

People

  • The investigator is qualified by education, training and experience and can show evidence of it (ICH E6(R3) 2.1.1).
  • There is enough time, enough qualified staff and adequate facilities for the whole trial (ICH E6(R3) 2.2.2).
  • Everyone with a delegated task is qualified and informed about the protocol, the product and their tasks (ICH E6(R3) 2.3.2).
  • The delegation record is current and lists each person and task (ICH E6(R3) 2.3.3).
  • CVs and trial-specific training records are filed, since both belong to the records that should exist before the trial starts (ICH E6(R3) C.3.1(m)).

Approvals and agreements

  • Dated, documented IRB or IEC approval or favorable opinion of the protocol, consent materials and participant information (ICH E6(R3) 2.4.2).
  • Regulatory authorization or notification where the country requires it (ICH E6(R3) 3.8.1).
  • The signed protocol or an alternative contract confirming agreement with the sponsor (ICH E6(R3) 2.5.1).
  • Signed agreements covering conduct by the protocol and GCP, data recording, record retention and access for monitoring, audit and inspection (ICH E6(R3) 3.6.3).
  • For US drug studies under an IND, a signed Form FDA 1572 with the list of subinvestigators (21 CFR 312.53(c)).

Records, product and systems

  • The investigator site file holds the current Investigator's Brochure, protocol, consent form versions, approvals and the sample data collection tools, all version controlled (ICH E6(R3) C.2.1).
  • Investigational product arrives only after the required IRB or IEC and regulatory approvals, with handling and storage instructions on file (ICH E6(R3) 3.15.3(a)).
  • Every person who uses a trial system has been trained on it and has their own access (ICH E6(R3) 4.3.2).
  • Equipment used for important trial activities is maintained and calibrated, and the records show it.
  • Normal ranges and laboratory documentation are on file for the tests the protocol uses.

How to use the checklist

Run it twice: once before the site initiation visit, so the monitor sees a site that is nearly ready, and again the week before the first participant visit, after any late changes to staff, consent versions or systems. Keep the dated, completed checklist with the site's records so the answer to the question are we ready is written down, not remembered.

The most common gap is people, not paper: a new coordinator who joined after the initiation visit and was never trained on the protocol or added to the delegation record. Check names against both lists every time.

Questions people also ask

Who decides that a site is ready to start?

The sponsor activates the site after confirming the investigator and staff have adequate qualifications, resources and facilities (ICH E6(R3) 3.11.4.5.2(a)), but the investigator is responsible for having the people and records in place.

Which records must exist before the first participant?

ICH E6(R3) marks them with an asterisk in the Essential Records Table of Appendix C: among them the protocol, IRB or IEC approval, signed agreements, investigator CVs, trial-specific training records and the delegation record (ICH E6(R3) C.2.5).

Is a site initiation visit the same as being ready?

No. The initiation visit trains the team on the protocol and checks preparation, but readiness also depends on approvals, product and system access that may arrive after it.

Does every staff member need trial-specific training?

Everyone with a delegated trial task needs the training that task requires beyond their usual training and experience (ICH E6(R3) 2.3.2).

Primary sources

  • ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
  • E6(R3) Good Clinical Practice, final guidance (U.S. Food and Drug Administration): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp
  • 21 CFR 312.53: Selecting investigators and monitors (eCFR): https://www.ecfr.gov/current/title-21/section-312.53
  • 21 CFR 312.60: General responsibilities of investigators (eCFR): https://www.ecfr.gov/current/title-21/section-312.60

Last reviewed

2026-11-14